Trodelvy
What Trodelvy is used for
Triple-Negative Breast Cancer Trodelvy is indicated: as monotherapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and who are not candidates for PD-1 or PD-L1 inhibitor therapy (see section 5.1). as monotherapy for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies, including at least one of them for advanced disease (see section 5.1) HR-Positive, HER2-Negative Breast Cancer Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Trodelvy
- Active substance
- sacituzumab govitecan
- Disease area
- Breast Neoplasms; Triple Negative Breast Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01FX06
- Marketing authorisation holder
- Gilead Sciences Ireland UC
- Authorised in the EU since
- 2021
Official information
In the USA
Same active substance: Trodelvy
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Trodelvy used for?
Triple-Negative Breast Cancer Trodelvy is indicated: as monotherapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and who are not candidates for PD-1 or PD-L1 inhibitor therapy (see section 5.1). as monotherapy for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies, including at least one of them for advanced disease (see section 5.1) HR-Positive, HER2-Negative Breast Cancer Trode…
What is the active substance in Trodelvy?
Trodelvy contains sacituzumab govitecan.
Who makes Trodelvy?
The EU marketing authorisation holder is Gilead Sciences Ireland UC.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU